01 Jun 2022
06:57 CEST |
IPSEN |
Ipsen Initiates a Share Buy-Back Program to Cover Its Employee Free Share-Allocation Plan
|
20103015 Pharmaceuticals |
Other financial transaction |
01 Jun 2022
06:57 CEST |
IPSEN |
Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés
|
20103015 Pharmaceuticals |
Other financial transaction |
26 May 2022
23:00 CEST |
IPSEN |
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
|
20103015 Pharmaceuticals |
Other subject |
26 May 2022
23:00 CEST |
IPSEN |
Ipsen : ASCO 2022 : De nouvelles données sur le Cabometyx® montrent des résultats encourageants en monothérapie et en thérapie combinée dans différents types de tumeurs, y compris dans le cancer du poumon non à petites cellules métastatique
|
20103015 Pharmaceuticals |
Other subject |
24 May 2022
19:30 CEST |
IPSEN |
Combined Shareholders’ Meeting of Ipsen S.A. Held on 24 May 2022
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
24 May 2022
19:30 CEST |
IPSEN |
ASSEMBLEE GENERALE MIXTE DES ACTIONNAIRES D’IPSEN S.A. DU 24 MAI 2022
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
24 May 2022
07:00 CEST |
IPSEN |
IPSEN : Descriptif du cadre réglementaire du programme de rachat d’actions soumis par le Conseil d’administration à l’approbation de l’Assemblée Générale Mixte des actionnaires du 24 mai 2022 (17ème résolution)
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
24 May 2022
07:00 CEST |
IPSEN |
IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders’ Meeting on 24 May 2022 (17th Resolution)
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
10 May 2022
18:00 CEST |
IPSEN |
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
10 May 2022
18:00 CEST |
IPSEN |
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
|
20103015 Pharmaceuticals |
Share history |
03 May 2022
07:30 CEST |
IPSEN |
IPSEN : INFORMATIONS CONCERNANT LA TENUE DE L’ASSEMBLEE GENERALE MIXTE DU 24 MAI 2022
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
03 May 2022
07:30 CEST |
IPSEN |
Ipsen: Information Relating to the Holding of the Combined Shareholders’ Meeting of 24 May 2022
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
03 May 2022
07:00 CEST |
IPSEN |
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
|
20103015 Pharmaceuticals |
Other subject |
03 May 2022
07:00 CEST |
IPSEN |
Ipsen : La Commission européenne approuve Cabometyx® comme traitement de deuxième ligne dans le cancer de la thyroïde différencié réfractaire à l’iode radioactif
|
20103015 Pharmaceuticals |
Other subject |
27 Apr 2022
06:57 CEST |
IPSEN |
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
|
20103015 Pharmaceuticals |
Sales |
27 Apr 2022
06:57 CEST |
IPSEN |
Ipsen réalise une solide performance de ses ventes au premier trimestre 2022
|
20103015 Pharmaceuticals |
Sales |
14 Apr 2022
06:55 CEST |
IPSEN |
Ipsen publishes its 2021 Universal Registration Document
|
20103015 Pharmaceuticals |
Legal |
14 Apr 2022
06:55 CEST |
IPSEN |
Ipsen publie son Document d’enregistrement universel 2021
|
20103015 Pharmaceuticals |
Legal |
08 Apr 2022
18:00 CEST |
IPSEN |
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
|
20103015 Pharmaceuticals |
Other subject |
08 Apr 2022
18:00 CEST |
IPSEN |
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Other subject |
25 Mar 2022
13:44 CET |
IPSEN |
Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer
|
20103015 Pharmaceuticals |
Other subject |
25 Mar 2022
13:44 CET |
IPSEN |
Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans le cancer de la thyroïde différencié réfractaire à l’iode radioactif
|
20103015 Pharmaceuticals |
Other subject |
16 Mar 2022
07:30 CET |
IPSEN |
Ipsen annonce son investissement dans un dispositif électronique innovant d’auto-injection de Somatuline® Autogel® / Somatuline® Depot (lanréotide), conçu pour améliorer l’expérience des patients
|
20103015 Pharmaceuticals |
Other subject |
16 Mar 2022
07:30 CET |
IPSEN |
Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience
|
20103015 Pharmaceuticals |
Other subject |
09 Mar 2022
18:00 CET |
IPSEN |
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Other subject |
09 Mar 2022
18:00 CET |
IPSEN |
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
|
20103015 Pharmaceuticals |
Other subject |
08 Mar 2022
07:00 CET |
IPSEN |
De nouvelles données rapportées par les patients ont démontré un haut niveau de satisfaction et ont révélé qu’un moins grand nombre de patients signalaient des douleurs au site d’injection avec Somatuline® Autogel®/Somatuline® Depot (lanréotide)
|
20103015 Pharmaceuticals |
Other subject |
08 Mar 2022
07:00 CET |
IPSEN |
Ipsen: New Patient-Reported Data Demonstrated High Satisfaction Levels and Fewer Patients Reporting Injection-site Pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
|
20103015 Pharmaceuticals |
Other subject |
16 Feb 2022
08:00 CET |
IPSEN |
Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital
|
20103015 Pharmaceuticals |
Other subject |
16 Feb 2022
08:00 CET |
IPSEN |
Ipsen nomme Catherine Abi-Habib en qualité de Vice-présidente exécutive, Stratégie, Transformation et Digital
|
20103015 Pharmaceuticals |
Other subject |
15 Feb 2022
07:00 CET |
IPSEN |
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
|
20103015 Pharmaceuticals |
Other subject |
15 Feb 2022
07:00 CET |
IPSEN |
Ipsen : Cabometyx® en combinaison avec Opdivo® a démontré des bénéfices continus en termes de survie et de qualité de vie sur une période de suivi de plus de deux ans dans l’étude de Phase III CheckMate -9ER
|
20103015 Pharmaceuticals |
Other subject |
11 Feb 2022
07:00 CET |
IPSEN |
Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business
|
20103015 Pharmaceuticals |
Sales |
11 Feb 2022
07:00 CET |
IPSEN |
Ipsen publie de solides résultats pour l’exercice 2021 et entre en négociations exclusives pour la cession de son activité en Santé Familiale
|
20103015 Pharmaceuticals |
Sales |
09 Feb 2022
18:00 CET |
IPSEN |
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
|
20103015 Pharmaceuticals |
Other subject |
09 Feb 2022
18:00 CET |
IPSEN |
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Other subject |
24 Jan 2022
07:00 CET |
IPSEN |
Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
|
20103015 Pharmaceuticals |
Other subject |
24 Jan 2022
07:00 CET |
IPSEN |
Santé Canada approuve le médicament Sohonos™ d’Ipsen (capsules de palovarotène) qui devient le premier traitement approuvé contre la fibrodysplasie ossifiante progressive
|
20103015 Pharmaceuticals |
Other subject |
21 Jan 2022
07:00 CET |
IPSEN |
Ipsen nomme Karen Witts en tant que membre indépendant du Conseil d’administration
|
20103015 Pharmaceuticals |
Other subject |
21 Jan 2022
07:00 CET |
IPSEN |
Ipsen Nominates Karen Witts as New Independent Board Member
|
20103015 Pharmaceuticals |
Other subject |
17 Jan 2022
18:00 CET |
IPSEN |
Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF
|
20103015 Pharmaceuticals |
Other subject |
17 Jan 2022
18:00 CET |
IPSEN |
Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF
|
20103015 Pharmaceuticals |
Other subject |
12 Jan 2022
18:00 CET |
IPSEN |
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Other subject |
12 Jan 2022
18:00 CET |
IPSEN |
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
|
20103015 Pharmaceuticals |
Other subject |
17 Dec 2021
07:00 CET |
IPSEN |
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership
|
20103015 Pharmaceuticals |
Alliances and agreements |
17 Dec 2021
07:00 CET |
IPSEN |
Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long terme
|
20103015 Pharmaceuticals |
Alliances and agreements |
09 Dec 2021
18:00 CET |
IPSEN |
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
|
20103015 Pharmaceuticals |
Other subject |
09 Dec 2021
18:00 CET |
IPSEN |
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Other subject |
09 Nov 2021
18:00 CET |
IPSEN |
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
|
20103015 Pharmaceuticals |
Other subject |
09 Nov 2021
18:00 CET |
IPSEN |
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Other subject |